1. Pink Sheet
  2. >>R&D

Podcast: Accelerating Antibiotics – Kevin Outterson And Joe Larsen Explain CARB-X

 
• By Laura Helbling

Podcast with CARB-X Executive Director Kevin Outterson and BARDA Acting Deputy Director Joe Larsen describes the work of the accelerator, which just announced the first eleven projects in its portfolio.

Antibiotic resistant bacteria closeup biofilm

The Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator, or CARB-X, announced the first eleven projects in its Powered by CARB-X portfolio March 30. The initial portfolio includes three projects on new classes of antibiotics and four projects on non-traditional products, such as immunotherapy or antibody-drug candidates.

We talked to Executive Director Kevin Outterson about narrowing down applicants from the wide interest and upcoming additions to the portfolio. Then Joe Larsen, Deputy Director of Biomedical Advanced Research and Development Authority (BARDA), discussed the beginning of CARB-X, how it fits with other work by BARDA and how the accelerator could also make private investment attractive again in this space

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

UK Health Data Research Service Looks ‘Encouraging’ For Industry, But Implementation Details Will Be Key

 
• By Anabel Costa-Ferreira

Marcus Vass and Vladimir Murovec of international law firm Osborne Clarke tell the Pink Sheet what the government's planned HDRS might mean for industry, and how it compares with the European Health Data Space.

EU Health Data Space May Speed Up R&D Through Access To Multi-Omics & Clinical Record Data

 
• By Eliza Slawther

The European Health Data Space framework will allow companies to accelerate R&D processes and identify new molecular targets faster by facilitating centralized access to certain types of high-quality data, Finland’s Orion Pharma says.

Pharma Industry Argues Tax, Other Incentives Better Than Tariffs

 
• By Jessica Merrill

Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a federal 232 investigation.

US FDA Guidance Roadblock: Writing Continues, But Publication Has Slowed Or Stopped

 
• By Derrick Gingery

Cuts to the FDA’s policy and legal personnel have prevented dozens of product-specific guidances for generic drug development from being published.

More from Pink Sheet

Recent and Upcoming FDA Advisory Committee Meetings

 
• By Sue Sutter

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

UK Health Data Research Service Looks ‘Encouraging’ For Industry, But Implementation Details Will Be Key

 
• By Anabel Costa-Ferreira

Marcus Vass and Vladimir Murovec of international law firm Osborne Clarke tell the Pink Sheet what the government's planned HDRS might mean for industry, and how it compares with the European Health Data Space.

EU Health Data Space May Speed Up R&D Through Access To Multi-Omics & Clinical Record Data

 
• By Eliza Slawther

The European Health Data Space framework will allow companies to accelerate R&D processes and identify new molecular targets faster by facilitating centralized access to certain types of high-quality data, Finland’s Orion Pharma says.